Research in brief: Empagliflozin for patients with heart failure and preserved ejection fraction
- PMID: 35078797
- PMCID: PMC8813021
- DOI: 10.7861/clinmed.rib.22.1.1
Research in brief: Empagliflozin for patients with heart failure and preserved ejection fraction
Keywords: empagliflozin; heart failure; preserved ejection fraction.
Comment on
-
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27. N Engl J Med. 2021. PMID: 34449189 Clinical Trial.
Similar articles
-
Evidence for empagliflozin in heart failure with preserved ejection fraction (HFpEF).Drug Ther Bull. 2023 Feb;61(2):22-23. doi: 10.1136/dtb.2022.000060. Epub 2022 Dec 12. Drug Ther Bull. 2023. PMID: 36600444
-
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.N Engl J Med. 2022 May 26;386(21):e57. doi: 10.1056/NEJMc2118470. N Engl J Med. 2022. PMID: 35613033 No abstract available.
-
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.N Engl J Med. 2022 May 26;386(21):e57. doi: 10.1056/NEJMc2118470. N Engl J Med. 2022. PMID: 35613032 No abstract available.
-
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.N Engl J Med. 2022 May 26;386(21):e57. doi: 10.1056/NEJMc2118470. N Engl J Med. 2022. PMID: 35613031 No abstract available.
-
Pharmacologic Management for Heart Failure and Emerging Therapies.Curr Cardiol Rep. 2017 Aug 24;19(10):94. doi: 10.1007/s11886-017-0899-x. Curr Cardiol Rep. 2017. PMID: 28840572 Review.
Cited by
-
Optimisation of strategies for management of heart failure with preserved ejection fraction.Clin Med (Lond). 2022 Mar;22(2):189. doi: 10.7861/clinmed.Let.22.2.4. Clin Med (Lond). 2022. PMID: 35304385 Free PMC article. No abstract available.
References
-
- Anker SD, Butler J, Filippatos G, et al. . Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–61. - PubMed
-
- McDonagh TA, Metra M, Adamo M, et al. . 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–726. - PubMed
-
- Solomon SD, McMurray JJV, Anand IS, et al. . Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609–20. - PubMed
-
- Zelniker TA, Wiviott SD, Raz I, et al. . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31–9. - PubMed
-
- Packer M, Anker SD, Butler J, et al. . Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413–24. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical